Featured Research

from universities, journals, and other organizations

Parkinson's Disease: Nicotine Reduces Levodopa-induced Dyskinesias

Date:
October 24, 2007
Source:
The Parkinson's Institute
Summary:
Research shows that intermittent nicotine treatment reduces medication-induced dyskinesias by as much as 50 percent. Dyskinesias is uncontrolled movements of the head and limbs.

The Parkinson's Institute and Clinical Center has announced research showing that intermittent nicotine treatment reduces medication-induced dyskinesias by as much as 50 percent in models of Parkinson's disease. Levodopa, the most common drug used to treat Parkinson's disease, is initially very effective.

However, long-term treatment often lessens efficacy and causes multiple complications, including abnormal involuntary movements, called dyskinesias. These uncontrolled movements of the head and limbs tend to worsen over time and can become as debilitating as Parkinson's disease itself.

Currently, there are only limited therapeutic options for dyskinesias, including reduction in levodopa dose, amantadine administration, and deep brain stimulation for a limited number of patients.

Most of the research on tobacco has focused on its detrimental health effects. Studies conducted over the last 40 years show that the incidence of Parkinson's disease is about 50 percent less in smokers than in the general population. Recent studies in experimental models suggest that the nicotine in smoke may be responsible for this neuroprotective effect.

In addition, this is the first research to show that nicotine may also reduce levodopa-induced dyskinesias. With an estimated 1.5 million Parkinson's disease patients in the United States, and levodopa being the top prescribed medication for Parkinson's disease, this study has far-reaching implications for the treatment of Parkinson's disease.

"Our hope is that this research represents a useful treatment strategy to reduce the dyskinesias that so many Parkinson's disease patients suffer, "said Dr. Maryka Quik of the Parkinson's Institute and Clinical Center in Sunnyvale. "Reducing the side effects of levodopa makes it a much more effective and long-term treatment."

Lead by senior research scientist, Maryka Quik, Ph.D., the research will be published in an upcoming issue of the Annals of Neurology.


Story Source:

The above story is based on materials provided by The Parkinson's Institute. Note: Materials may be edited for content and length.


Cite This Page:

The Parkinson's Institute. "Parkinson's Disease: Nicotine Reduces Levodopa-induced Dyskinesias." ScienceDaily. ScienceDaily, 24 October 2007. <www.sciencedaily.com/releases/2007/10/071024093555.htm>.
The Parkinson's Institute. (2007, October 24). Parkinson's Disease: Nicotine Reduces Levodopa-induced Dyskinesias. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2007/10/071024093555.htm
The Parkinson's Institute. "Parkinson's Disease: Nicotine Reduces Levodopa-induced Dyskinesias." ScienceDaily. www.sciencedaily.com/releases/2007/10/071024093555.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins